E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Seizures in patients with suspected cerebral glioma |
|
E.1.1.1 | Medical condition in easily understood language |
Seizures in patients with suspected primary brain tumour |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018338 |
E.1.2 | Term | Glioma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061030 |
E.1.2 | Term | Brain tumour |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This aim of the study is to investigate whether use of levetiracetam before surgery will help to prevent patients with suspected brain tumours developing seizures after their surgery.
The patients will have surgery planned and will have not experienced a seizure.
We will give half of these patients current standard care (no anti-epileptic drug) and the other half will receive an anti epileptic drug called levetiracetam before surgery and for up to one year after to see if this drug will reduce their risk of having seizures. Using a drug in this manner is called prophylactic use.
|
|
E.2.2 | Secondary objectives of the trial |
In patients with a suspected brain tumour, that have never had a seizure, does taking preventative (taken before any seizure) levetiracetam: • Delay the time for a patient to have their first seizure. • Delay the time for a patient to have their first tonic-clonic (or convulsive) seizure. • Have any affect on patients’ mood, personality, energy levels (tiredness) or memory. • Have any effect on how the severe the first seizure is if it happens. • Have an impact on the patients quality of life (wellbeing ) • Have an impact on a patient’s survival without cancer relapse. • Have an impact on a patient’s survival. • Reduces costs to the NHS and personal social services (PSS) over the 12 months trial follow-up.
In addition the study will investigate if taking preventative (taken before any seizure) levetiracetam is cost effective. The cost effectiveness will be measured by looking at cost change per Quality adjusted life year (QALY) over a 12 month period. A Quality adjusted life year is |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1)Patients with suspected cerebral glioma on MRI
2)Capable of giving informed consent
3)Patients must be ≥ 16 years old
4)Patients must have a Karnofsky performance status ≥70
5)Patients must be able to safely swallow pills 6)Planned surgery for presumed glioma (biopsy or resection)
|
|
E.4 | Principal exclusion criteria |
1)Pregnant 2)History of any type of seizure for at least 10 years prior to randomisation
3)Known Severe Chronic Kidney Disease (CKD4 - eGFR < 30ml/min) 4)Concomitant methotrexate 5)Concomitant AED (including use for other reasons (e.g. pain)) 6)Concomitant benzodiazepines 7)Hypersensitivity to levetiracetam
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Outcome is one year risk of first seizure.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluated at clinic visits at 3, 6, 9 and 12 months. |
|
E.5.2 | Secondary end point(s) |
Time to first seizure Time to first tonic clonic seizure Mood, personality, fatigue and memory Severity of first seizure Quality of life Progression free survival Overall survival Costs to the NHS (National Health Service) and personal social services (PSS) cost-effectiveness
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluated at clinic visits at 3, 6, 9 and 12 months and through monthly telephone calls from a research nurse. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
no anti-epileptic drug (Standard of Care) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 1 |